Mabpharm Limited (HKG:2181)
Hong Kong · Delayed Price · Currency is HKD 0.5100
0.00 (0.00%)
Feb 11, 2026, 3:33 PM HKT
Mabpharm Market Cap
Mabpharm has a market cap or net worth of 2.1 billion as of February 13, 2026. Its market cap has increased by 100.00% in one year.
Market Cap
2.10B
Enterprise Value
2.33B
Revenue
464.53M
Ranking
n/a
PE Ratio
n/a
Stock Price
0.51
Market Cap Chart
Since May 31, 2019, Mabpharm's market cap has decreased from 4.99B to 2.10B, a decrease of -57.85%. That is a compound annual growth rate of -12.08%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 12, 2026 | 2.10B | 2.00% |
| Dec 31, 2025 | 2.06B | 78.57% |
| Dec 31, 2024 | 1.15B | -39.13% |
| Dec 29, 2023 | 1.90B | 5.75% |
| Dec 30, 2022 | 1.79B | -56.50% |
| Dec 31, 2021 | 4.12B | -4.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Jiangsu Recbio Technology | 3.05B |
| Clover Biopharmaceuticals | 2.86B |
| SinoMab BioScience | 2.48B |
| Antengene Corporation | 2.36B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 2.32B |
| Frontage Holdings | 2.19B |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 1.98B |
| Zhaoke Ophthalmology | 1.90B |